COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: urban-gro, Inc (von First Berlin Equity Research GmbH): Kaufen
First Berlin Equity Research reaffirms BUY rating on urban-gro, Inc. following DEA's approval of cannabis rescheduling, anticipating positive effects on sector and company. Full year targets confirmed -
-
COMMUNIQUÉ DE PRESSE
Kapsch TrafficCom AG: Sale of non-core strategic assets.
Kapsch TrafficCom AG sells non-core strategic assets for close to EUR 11 million, optimizing financial results. Proceeds will impact financial reports of 2023/24. Key strategy realignment decisions are made to enhance cash flows and reduce gearing ratio -
COMMUNIQUÉ DE PRESSE
HRS ANNONCE L'INITIATION DE COUVERTURE DE SON TITRE PAR EUROLAND CORPORATE
HRS annonce l'initiation de couverture de son titre par Euroland Corporate. EuroLand Corporate a publié une étude soulignant une valeur d'équilibre de 11,50€ par action pour HRS, comparée à un cours de clôture de 5,08€ le 30 avril 2023 -
-
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
MindBio Therapeutics Corp. showcases women's health trials and upcoming data presentation on Phase 2A trial of MB22001 for Major Depressive Disorder. Company pioneering microdosing LSD for mental health conditions -
-
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
MindBio Therapeutics Corp. presents groundbreaking women's health trials for microdosing treatments, showcasing Dr. Rachael Sumner and upcoming data release on Phase 2A trial results. Chief Executive Justin Hanka discusses future growth plans -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: European Healthcare Acquisition & Growth Company B.V. announces change in CEO position
European Healthcare Acquisition & Growth Company B.V. announces change in CEO position. Dr. Thomas Rudolph appointed as new CEO and compliance officer following Dr. Cornelius H. Baur's resignation
